← All trials
NCT06779253
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2025
- Primary completion
- May 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- Jan 16, 2025
- Last posted
- Jan 20, 2025
- Enrollment
- 38
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Abbisko Therapeutics Co, LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.